Pharmaceuticals

FUDANZHANGJIANG

FUDANZHANGJIANG released FY2026 Q1 earnings on April 30 After-Market (BJT), actual revenue HKD 168.99 M, actual EPS HKD 0.0113

FUDANZHANGJIANG to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

FUDANZHANGJIANG FY2025 Earnings Release Scheduled for March 30 During-Market BJT

FUDANZHANGJIANG released FY2025 earnings on February 27 During-Market (BJT), actual revenue HKD 749.55 M, actual EPS HKD -0.166

FUDANZHANGJIANG released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue HKD 149.82 M, actual EPS HKD -0.1518

Fudan Zhangjiang Anticipates Net Loss of RMB 120 Million to 180 Million for 2025

Fudan Zhangjiang Receives Acceptance for Clinical Trial Application of FZ-P001 Sodium

Fudan Zhangjiang Changes A-Share Raised Funds Purpose to Support Photodynamic Drug R&D

FUDANZHANGJIANG released FY2025 Q3 earnings on October 30 After-Market BJT, actual revenue HKD 175.99 M, actual EPS HKD -0.0906

FUDANZHANGJIANG released FY2025 9 Months Earnings on October 30 After-Market BJT, actual revenue HKD 598.71 M, actual EPS HKD -0.0846

FUDANZHANGJIANG to Release FY2025 Q3 Earnings on October 30 After-Market BJT

Affiliate of Fudan Zijang's Obeticholic Acid Tablets Application for Market Approval Rejected

FUDANZHANGJIANG released FY2025 Semi-Annual earnings on August 12 After-Market (BJT), actual revenue HKD 422.36 M, actual EPS HKD 0.0059

FUDANZHANGJIANG released FY2025 Q2 earnings on August 12 After-Market BJT, actual revenue HKD 230.04 M, actual EPS HKD 0.0032

Fudan Zhangjiang Reports 91.89% Drop in Net Profit in H1 2025

FUDANZHANGJIANG to Release FY2025 Semi-Annual Earnings on August 12, 2025 (BJT)

Wang Haibo Sells 4.2707 Million Shares of Fudan Zhangjiang

Fudan Zhangjiang Announces DC Platform Development Progress

Yang Zongmeng's 减持 of Fudan Zhangjiang Shares Triggers 1% Threshold

Shanghai Fudan Zhangjiang Signs Structured Deposit Agreement with China Merchants Bank

I.CENTURY HLDG

KOS TALENT GP

RIVERINE CHINA

NEW AMANTE

REDCO HEALTHY

C&N HOLDINGS

XL2CSOPHYNIX

ZXZN QI-HOUSE

DIGIT HOLLYWOOD

RICI HEALTH

688505

600000

01349

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. has invested RMB210 million in a low-risk structured deposit with SPD Bank. The deposit offers a floating annualized return of 0.70% to 2.05% over 87 days, linked to the EUR/USD exchange rate. This transaction exceeds 5% but is below 25% of applicable percentage ratios, requiring disclosure but not shareholder approval. The investment aims to optimize short-term liquidity while maintaining principal security, reflecting the company's strategy to manage idle funds through conservative financial products.

Tip Ranks

Fudan-Zhangjiang

SPD Bank

Fudan Zhangjiang Invests RMB210 Million in Low-Risk SPD Bank Structured Deposit

01385

Shanghai Fudan announced its performance for the fiscal year 2025, with operating revenue of 3.982 billion RMB, an increase of 10.9% year-on-year. It recorded a net profit of 232 million RMB, a decline of 59.4%, with earnings per share of 0.28 RMB. The final dividend is 0.58 RMB per 10 shares

AASTOCKS

SHANGHAI FUDAN

"Performance" Shanghai Fudan's annual net profit is 232 million RMB, a decrease of 59.4%, with a dividend of 0.58 RMB per 10 shares

159316

159837

520690

516500

588130

520880

159992

159849

159506

512290

Fudan-Zhangjiang issued a profit warning, expecting a net loss of between 120 million and 180 million RMB for the fiscal year 2025, compared to a net profit of 39.73 million RMB in the previous year. The reason is that the group is actively promoting the progress of research and development projects, with R&D investment as a proportion of operating income continuously increasing; the product Libo Duo has not been selected for the national procurement catalog, and the company has accordingly adjusted its sales strategy to lower market retail prices, resulting in a reduction of approximately 100 million RMB in profit contribution from the products

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Guotai CSI Bio-medicine ETF

"Profit Warning" Fudan-Zhangjiang estimates a full-year loss of 120 million to 180 million RMB

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. has invested RMB110 million in low-risk structured deposits from China Merchants Bank. The 83-day term products offer an expected annual return of 1.00%–1.65% linked to gold. This investment is classified as a cautious-risk transaction under Hong Kong listing rules, requiring reporting but not shareholder approval. The company aims to enhance returns on surplus cash while maintaining its risk profile and capital structure. Fudan-Zhangjiang is a biopharmaceutical firm focused on research and development in the healthcare sector, with a market cap of HK$965 million.

Fudan-Zhangjiang Deploys RMB110 Million in Low-Risk Structured Deposits

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. has invested RMB150 million in a low-risk structured deposit with Bank of China, utilizing idle funds from its A-share public offering. The 84-day deposit, linked to the AUD/USD rate, offers a floating annualized return of 0.35% to 1.6539%. This transaction is disclosable under Hong Kong listing rules, reflecting the company's conservative treasury management strategy.

Fudan-Zhangjiang Places RMB150 Million in Low-Risk Bank of China Structured Deposit

00434

The article highlights three Asian penny stocks, including Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Ltd, Boyaa Interactive International, and Zhongzhu Healthcare Holding Ltd, which show potential for growth. Shanghai Fudan-Zhangjiang focuses on bio-pharmaceuticals with a market cap of HK$7.87 billion but is currently unprofitable. Boyaa Interactive, valued at HK$2.78 billion, has seen significant earnings growth despite potential profit decreases. Zhongzhu Healthcare, with a market cap of CN¥4.87 billion, is also unprofitable but has reduced its net loss year-over-year. These stocks are attracting investor interest amid a complex market landscape.

Simplywall

BOYAA

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd And 2 Other Asian Penny Stocks To Watch Closely